Pharmasset Further Refines Its Hepatitis C Polymerase Inhibitor
Share
Follow Us
The Editors at Hepatitis Central
January 26, 2010
An isomer of PSI -7851 (a polymerase inhibitor that has already demonstrated encouraging clinical results for Hepatitis C), Pharmasset believes that PSI-7977 would be more potent and better suited for manufacturing. Hence, Pharmasset has initiated a Phase 2a trial to test this substance on treatment naïve participants with Hepatitis C genotype 1.
Pharmasset Initiates Phase 2a Trial With PSI-7977, A Chirally Pure Isomer Of PSI-7851
Article Date: 23 Jan 2010
Pharmasset, Inc. (Nasdaq: VRUS) announces the initiation of a 28-day Phase 2a study with PSI-7977, a chirally pure isomer form of PSI-7851, a nucleotide analog polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV). The trial will evaluate various doses of PSI-7977 in combination with Pegasys (peginterferon alfa 2a) and Copegus (ribavirin) in patients with HCV genotype 1 who have not been treated previously.
Continue reading this entire article:
http://www.medicalnewstoday.com/articles/176924.php
